Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility
Journal of Molecular Medicine · 2026-12 · 104 (1)
DOI: 10.1007/s00109-026-02670-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, online erschienen am 31.03.2026. Verfasst von Michelli Fontana und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, Federal University of Fronteira Sul, Chapecó, SC, Brazil. Hauptthemen laut MEDLINE: Chronic Urticaria, Signal Transduction, Receptors, Purinergic, Urticaria. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina, Universidade Federal da Fronteira Sul.
Abstract (Originalsprache)
Urticaria is a skin lesion characterized by a central swelling area of varying sizes, usually surrounded by erythema and accompanied by itching or a burning sensation. Recurrence for at least six weeks characterizes chronic urticaria, a condition that has no cure, only treatment to minimize symptoms. The available pharmacological therapies show variable success and do not regulate the inflammatory balance of the skin in the long term. Therefore, it is essential to evaluate treatment possibilities to seek new symptom management approaches. In this regard, this study addresses the currently available therapies, linking the disease’s pathophysiology with purinergic signaling to identify new therapeutic possibilities. In this respect, extracellular ATP is related to mast cells degranulation in the skin, which affects urticaria. Considering other dermatological diseases that present an inflammatory response, the purinergic receptor P2X7 is related to inflammation in several pathological skin conditions, such as psoriasis, dermatitis and pruritus. P2X7 engagement also contributes to ATP-mediated mast cell degranulation. Therefore, evaluating the expression of purinergic receptors in the skin of patients with chronic spontaneous urticaria, along with ATP levels in urticarial lesions, may help elucidate the therapeutic potential of targeting this purinergic pathway. Key messages Many patients are refractory to licensed therapies of H1antihistamines and omalizumab. Cyclosporine and other immunosuppressants are studied for refractory patients. Probiotics as adjuncts to antihistamines are studied to reduce symptoms. P2X7 receptor links to inflammatory skin diseases and may offer new therapy approach. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical School, Federal University of Fronteira Sul, Chapecó, SC, Brazil.
- Medical School, Catholic University of Pelotas, Pelotas, RS, Brazil.
- Graduate Program in Medical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil.
- Graduate Program in Medical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil. margarete.bagatini@uffs.edu.br.
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação de Amparo à Pesquisa e Inovação do Estado de Santa Catarina
- Universidade Federal da Fronteira Sul
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Fontana, M., Simões, J. L. B., de Carvalho Braga, G., Fontana, M., Filho, J. C. M., & Bagatini, M. D. (2026). Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02670-0
Vancouver
Fontana M, Simões JLB, de Carvalho Braga G, Fontana M, Filho JCM, Bagatini MD. Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02670-0
BibTeX
@article{Fontana2026,
author = {Fontana, Michelli and Simões, Júlia Leão Batista and de Carvalho Braga, Geórgia and Fontana, Mauricio and Filho, João Carlos Menta and Bagatini, Margarete Dulce},
title = {Chronic spontaneous urticaria treatments and purinergic signaling: a therapeutic possibility},
journal = {Journal of Molecular Medicine},
year = {2026},
volume = {104},
number = {1},
doi = {10.1007/s00109-026-02670-0}
}
EUVIMED